未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Moebus, V.; Jackisch, C.; Luck, H. J.; du Bois, A.; Thomssen, C.; Kuhn, W.; Nitz, U.; Schneeweiss, A.; Huober, J.; Harbeck, N.; von Minckwitz, G.; Runnebaum, I. B.; Hinke, A.; Konecny, G. E.; Untch, M.; Kurbacher, C. 分享 收藏 Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014)Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Moebus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Boehmer, S.; Kreienberg, R.; Du Bois, A.; Sattler, D.; Thomssen, C.; Kiechle, M.; Jaenicke, F.; Wallwiener, D.; Harbeck, N.; Kuhn, W. 分享 收藏 Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2-early breast cancer: WSG-AGO EC-Doc TrialGluz, O.; Liedtke, C.; Huober, J.; Peyro-Saint-Paul, H.; Kates, R. E.; Kreipe, H. H.; Hartmann, A.; Pelz, E.; Erber, R.; Mohrmann, S.; Moebus, V.; Augustin, D.; Hoffmann, G.; Thomssen, C.; Jaenicke, F.; Kiechle, M.; Wallwiener, D.; Kuhn, W.; Nitz, U.; Harbeck, N. 分享 收藏 Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expressionNitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Moebus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Boehmer, S.; Kreienberg, R.; Du Bois, A.; Sattler, D.; Thomssen, C.; Kiechle, M.; Jaenicke, F.; Wallwiener, D.; Harbeck, N.; Kuhn, W. 分享 收藏 分享 收藏 RE: Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial ResponseMoebus, Volker; Jackisch, Christian; Schneeweiss, Andreas; Huober, Jens; Lueck, Hans-Joachim; Du Bois, Andreas; Thomssen, Christoph; Kurbacher, Christian; Kuhn, Walther; Nitz, Ulrike A.; Runnebaum, Ingo B.; Hinke, Axel; Kreienberg, Rolf; Untch, Michael 分享 收藏 分享 收藏 Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical TrialMoebus, Volker; Jackisch, Christian; Schneeweiss, Andreas; Huober, Jens; Lueck, Hans-Joachim; du Bois, Andreas; Thomssen, Christoph; Kurbacher, Christian; Kuhn, Walther; Nitz, Ulrike; Runnebaum, Ingo B.; Hinke, Axel; Kreienberg, Rolf; Untch, Michael 分享 收藏 分享 收藏 Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with 4 positive lymph nodes.Moebus, V.; Schneeweiss, A.; du Bois, A.; Lueck, H-J; Eustermann, H.; Kuhn, W.; Kurbacher, C.; Nitz, U.; Kreienberg, R.; Jackisch, C.; Huober, J.; Thomssen, C.; Untch, M. 分享 收藏 Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer Results from the EC -Doc Trial.Gluz, O.; Erber, R.; Kates, R.; Kreipe, H.; Bartels, A.; Liedtke, C.; Pelz, E.; Huober, J.; Kuhn, W.; Nitz, U.; Hartmann, A.; Harbeck, N.; Bruenner, N. 分享 收藏 Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer An Analysis of the WSG EC-Doc TrialHuober, J.; Gluz, O.; Hartmann, A.; Kates, R.; Kreipe, H. H.; Pelz, E.; Thomssen, C.; Fischer, H. H.; Moebus, V.; Augustin, D.; Weiss, E.; Erber, R.; Liedtke, C.; Kuhn, W.; Nitz, U.; Harbeck, N. 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
CANCER RESEARCH.png)
